Cutting-Edge Drug Shows Promise for Patients with NRAS-Driven Melanoma
Researchers at the Huntsman Cancer Institute have identified a potential new treatment for NRAS-driven melanoma using the drug daraxonrasib. Preclinical models showed significant tumor shrinkage, offering hope for patients with this aggressive form of skin cancer.
Why it matters
This development addresses a critical unmet need for patients with recalcitrant, mutation-driven cancers that have historically been difficult to treat.
Newswise — A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease. Martin McMahon, PhD , senior director of preclinical translation at Huntsman Cancer Institute and professor of dermatology at the U, evaluated an investigative compound of the drug daraxonrasib in NRAS -driven melanoma . NRAS -driven melanoma is an aggressive type of skin cancer driven by mutations in the NRAS gene. Daraxonrasib, developed by Revolution Medicines , targets and inhibits RAS, a protein that drives cancer when altered. NRAS is a subtype of RAS that is mutated in roughly a quarter of melanoma cases.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in